Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.
about
Acute lymphoblastic leukaemiaGenetic abnormalities associated with acute lymphoblastic leukemiaBest Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on AsparaginaseX-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and risk of childhood acute lymphoblastic leukemia: a meta-analysis.Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.Blood consult: therapeutic strategy and complications in the adolescent and young adult with acute lymphoblastic leukemiaRationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival.A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.Acute lymphoblastic leukemia in children and adolescents: prognostic factors and analysis of survivalEradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)Advances in the Biology of Acute Lymphoblastic Leukemia-From Genomics to the ClinicThe adolescent and young adult with cancer: state of the art-- acute leukemias.Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis.Therapeutic approaches to haematological malignancies in adolescents and young adults.Epstein-Barr virus and regulatory T cells in Egyptian paediatric patients with acute B lymphoblastic leukaemia.Disparities in Adolescents and Young Adults With CancerEpstein-Barr virus-positive systemic NK/T-cell lymphomas in children: report of six cases.Real-world outcomes of treatment for acute lymphoblastic leukemia during adolescence in a financially restricted environment: Results at a single center in Latin America.Invasive fungal infections in ALL: a new 'growth' area.Sink or Collaborate: How the Immersive Model Has Helped Address Typical Adolescent and Young Adult Barriers at a Single Institution and Kept the Adolescent and Young Adult Program Afloat.Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study.
P2860
Q24602387-EEDDFE2A-051E-4A99-B798-F4812EF39168Q26753823-CFD02735-8972-4DA1-8317-D04BDDAE7462Q26784116-AD0F09E8-3713-49C8-A346-4DE64445869EQ31057165-C244F6DA-67D4-4F2B-B9E5-E0C13E8AE304Q33605181-B4D1C23B-0795-473B-8015-9C1CB1728A78Q33711119-D00C4C8E-A372-4A09-BBF8-417654177F1DQ33762835-7CFCD302-6518-412D-9F17-E7FFED9B0483Q34009088-1E4FF8B2-F24B-4FBA-B95E-A711512053F6Q34325815-1D8593D0-8323-4DEA-9B8C-1D60A996CF39Q34606414-1D933FA7-B036-49E3-8D32-718CC1CEE1A7Q35004970-584696BF-4AB5-4FA3-AB34-A64FED50CB5DQ35901969-6880AD98-3EF9-45FA-ACBF-E6E0E5A6092FQ35904943-6D0BC76E-816A-47D1-B8D2-CF5078B3A295Q36616666-4BFD08C6-F600-4F04-966B-45D93E255025Q36752634-B38203AA-C400-4946-B436-48B6B96E20A5Q37134753-B41D9FC2-AE25-4F95-A16B-E19529FC0C3AQ37695157-CA31343A-DD81-48D8-8DC9-02D7C6273ABDQ37990381-8A0F880D-BEB5-4EB1-8F67-030D9F8A0A5FQ38134399-67B6107E-069F-4C65-82DD-1CC64A75D9BEQ38882894-34A2AE27-5FBE-4BE5-A228-FF3B589D4A73Q39008035-55E50A2C-F3DE-45EA-B2A8-47007D2DCCF3Q40302439-D3CAE22B-B029-40B8-999F-AFDB957EC38CQ40427765-AF146AC6-BF90-4369-879F-A06F5C833A22Q40695580-14632049-44F2-4D3A-99F9-A84947900149Q44707233-F1AA9F79-B68C-438F-AD04-FE65D8EA01C7Q46424183-54175324-FD1C-4F74-97DD-B53A5F2FE9C8
P2860
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.
@en
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.
@nl
type
label
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.
@en
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.
@nl
prefLabel
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.
@en
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.
@nl
P2860
P1476
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.
@en
P2093
Eric S Schafer
P2860
P304
P356
10.1038/NRCLINONC.2011.77
P407
P577
2011-05-31T00:00:00Z